{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:58:40Z","timestamp":1775487520752,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s13760-020-01499-9","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T08:03:18Z","timestamp":1606204998000},"page":"231-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experience"],"prefix":"10.1007","volume":"121","author":[{"given":"Hepsen Mine","family":"Serin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8719-0665","authenticated-orcid":false,"given":"Sanem","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdem","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seda","family":"Kanmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cenk","family":"Eraslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul","family":"Aktan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Tekgul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarenur","family":"Gokben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"1499_CR1","first-page":"1513","volume":"21","author":"IA Ketelslegers","year":"2015","unstructured":"Ketelslegers IA, Van Pelt DE, Bryde S et al (2015) Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. MultScler 21:1513\u20131520","journal-title":"MultScler"},{"key":"1499_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/cen3.12434","volume":"9","author":"K Fujihara","year":"2018","unstructured":"Fujihara K, Sato DK, Nakashima I et al (2018) Myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease: an overview. Clin Exp Neuroimmunol 9:48\u201355. https:\/\/doi.org\/10.1111\/cen3.12434","journal-title":"Clin Exp Neuroimmunol"},{"key":"1499_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","volume":"13","author":"KC O\u2019Connor","year":"2007","unstructured":"O\u2019Connor KC, McLaughlin KA, De Jager PL et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211\u2013217","journal-title":"Nat Med"},{"key":"1499_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","volume":"15","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Dale RC, Brilot F (2016) Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15:307\u2013324","journal-title":"Autoimmun Rev"},{"key":"1499_CR5","first-page":"1243","volume":"234","author":"H Tegetmeyer","year":"2017","unstructured":"Tegetmeyer H, Merkenschlager A (2017) Anti-myelin oligodendrocyte glycoprotein antibodies in paediatric patients with optic neuritis (in German). KlinMonblAugenheilkd 234:1243\u20131249","journal-title":"KlinMonblAugenheilkd"},{"key":"1499_CR6","first-page":"e81","volume":"2","author":"Y Hacohen","year":"2015","unstructured":"Hacohen Y, Absoud M, Deiva K et al (2015) Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. NeurolNeuroimmunolNeuroinflamm 2:e81","journal-title":"NeurolNeuroimmunolNeuroinflamm"},{"key":"1499_CR7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","volume":"89","author":"E-M Hennes","year":"2017","unstructured":"Hennes E-M, Baumann M, Schanda K et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89:900\u2013908","journal-title":"Neurology"},{"key":"1499_CR8","first-page":"1","volume":"26","author":"B Konuskan","year":"2018","unstructured":"Konuskan B, Yildirim M, Gocmen R et al (2018) Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. MultSclerRelatDisord 26:1\u20137","journal-title":"MultSclerRelatDisord"},{"key":"1499_CR9","first-page":"478","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMANeurol 75:478\u2013487","journal-title":"JAMANeurol"},{"key":"1499_CR10","doi-asserted-by":"publisher","first-page":"102005","DOI":"10.1016\/j.msard.2020.102005","volume":"41","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Hashimoto B, Izaki S et al (2020) Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: blood-brain barrier breakdown and peripheral plasmablasts. MultSclerRelatDisord 41:102005. https:\/\/doi.org\/10.1016\/j.msard.2020.102005","journal-title":"MultSclerRelatDisord"},{"key":"1499_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"1499_CR12","first-page":"1261","volume":"19","author":"LB Krupp","year":"2013","unstructured":"Krupp LB, Tardieu M, Amato MP et al (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. MultScler 19:1261\u20131267","journal-title":"MultScler"},{"key":"1499_CR13","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fneur.2019.00868","volume":"10","author":"L Mao","year":"2019","unstructured":"Mao L, Yang L, Kessi M et al (2019) Myelin oligodendrocyte glycoprotein (MOG) antibody diseases in children in central south china: clinical features, treatments, influencing factors, and outcomes. Front Neurol 10:868. https:\/\/doi.org\/10.3389\/fneur.2019.00868","journal-title":"Front Neurol"},{"key":"1499_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E et al (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J NeurolNeurosurg Psychiatry 89:127\u2013137","journal-title":"J NeurolNeurosurg Psychiatry"},{"key":"1499_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","volume":"86","author":"M Baumann","year":"2015","unstructured":"Baumann M, Sahin K, Lechner C et al (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J NeurolNeurosurg Psychiatry 86:265\u2013272","journal-title":"J NeurolNeurosurg Psychiatry"},{"key":"1499_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Kleiter I, Ruprecht K et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement\u2014frequency, presentation and outcome. J Neuroinflamm 13:281","journal-title":"J Neuroinflamm"},{"key":"1499_CR17","first-page":"174","volume":"22","author":"C Fernandez-Carbonell","year":"2016","unstructured":"Fernandez-Carbonell C, Vargas-Lowy D, Musallam A et al (2016) Clinical and MRI phenotype of children with MOG antibodies. MultScler 22:174\u2013184","journal-title":"MultScler"},{"key":"1499_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00415-018-8781-3","volume":"265","author":"M Baumann","year":"2018","unstructured":"Baumann M, Grams A, Djurdjevic T et al (2018) MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol 265:845\u2013855","journal-title":"J Neurol"},{"key":"1499_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fneur.2018.00217","volume":"9","author":"GR dos Passos","year":"2018","unstructured":"dos Passos GR, Oliveira LM, da Costa BK et al (2018) MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 9:217","journal-title":"Front Neurol"},{"key":"1499_CR20","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","volume":"80","author":"R Marignier","year":"2013","unstructured":"Marignier R, Bernard-Valnet R, Giraudon P et al (2013) Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 80:2194\u20132200","journal-title":"Neurology"},{"key":"1499_CR21","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s11427-015-4997-y","volume":"59","author":"Y Yan","year":"2016","unstructured":"Yan Y, Li Y, Fu Y et al (2016) Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci 59:1270\u20131281","journal-title":"Sci China Life Sci"},{"key":"1499_CR22","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/dmcn.13703","volume":"60","author":"S Duignan","year":"2018","unstructured":"Duignan S, Wright S, Rossor T et al (2018) Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 60:958\u2013962","journal-title":"Dev Med Child Neurol"},{"key":"1499_CR23","first-page":"e12","volume":"1","author":"RC Dale","year":"2014","unstructured":"Dale RC, Tantsis EM, Merheb V et al (2014) Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. NeurolNeuroimmunolNeuroinflamm 1:e12","journal-title":"NeurolNeuroimmunolNeuroinflamm"},{"key":"1499_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","volume":"88","author":"J Hyun","year":"2017","unstructured":"Hyun J, Woodhall MR, Kim S et al (2017) Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J NeurolNeurosurg Psychiatry 88:811\u2013817","journal-title":"J NeurolNeurosurg Psychiatry"},{"key":"1499_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518811597","author":"LM Oliveira","year":"2018","unstructured":"Oliveira LM, Ap\u00f3stolos-Pereira SL, Pitombeira MS et al (2018) Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. MultScler. https:\/\/doi.org\/10.1177\/1352458518811597","journal-title":"MultScler."},{"key":"1499_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflamm 13:279","journal-title":"J Neuroinflamm"},{"issue":"8","key":"1499_CR27","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1177\/1352458512470310","volume":"19","author":"K Rost\u00e1sy","year":"2013","unstructured":"Rost\u00e1sy K, Mader S, Hennes EM et al (2013) Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. MultScler 19(8):1052\u20131059. https:\/\/doi.org\/10.1177\/1352458512470310","journal-title":"MultScler"},{"key":"1499_CR28","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E et al (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90:e1858\u2013e1869. https:\/\/doi.org\/10.1212\/WNL.0000000000005560","journal-title":"Neurology"},{"key":"1499_CR29","first-page":"1355","volume":"75","author":"AS L\u00f3pez-Chiriboga","year":"2018","unstructured":"L\u00f3pez-Chiriboga AS, Majed M, Fryer J, Dubey D et al (2018) Association of MOG-IgGserostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMANeurol 75:1355","journal-title":"JAMANeurol"},{"key":"1499_CR30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2940","author":"P Waters","year":"2019","unstructured":"Waters P, Fadda G, Woodhall M et al (2019) Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMANeurol. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2940","journal-title":"JAMANeurol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01499-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-020-01499-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01499-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T15:11:11Z","timestamp":1615129871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-020-01499-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1007\/s13760-020-01499-9","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"28 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Local Ethics Committee of Ege University and carried out in accordance with the principles of the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The consent form was received from the parents of the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}